Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsEli Lilly and Company (LLY)
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.63
-3.85%
HEALTHCARE · Cap: $15.52M
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 398310% more annual revenue ($65.18B vs $16.36M). LLY leads profitability with a 31.7% profit margin vs -4.3%. LLY earns a higher WallStSmart Score of 78/100 (B+).
HKPD
Avoid22
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+81.4%
Fair Value
$4.29
Current Price
$0.63
$3.67 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 3.0%
ROE of -13.4% — below average capital efficiency
Revenue declined 35.7%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HKPD
The strongest argument for HKPD centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Operating Margin, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
HKPD profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 22/100), backed by strong 31.7% margins and 42.6% revenue growth. HKPD offers better value entry with a 81.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other PHARMACEUTICAL RETAILERS Stocks
Want to dig deeper into these stocks?